María Varela, MD, PhD, discusses the findings from a real-life analysis to confirm the benefit of regorafenib as treatment of patients with hepatocellular carcinoma who have progressed on prior sorafenib. Regorafenib was approved by the FDA for second-line treatment in this patient population based on data from the phase III RESORCE trial.
María Varela, MD, PhD, a pathologist in the Liver Unit at the Hospital Universitario Central de Asturias, discusses the findings from a real-life analysis to confirm the benefit of regorafenib (Stivarga) as treatment of patients with hepatocellular carcinoma (HCC) who have progressed on prior sorafenib (Nexavar). Regorafenib was approved by the FDA for second-line treatment in this patient population based on data from the phase III RESORCE trial.
If patients with HCC moved to regorafenib at the time of radiographic progression, they obtained better survival with regorafenib than if they stayed on sorafenib, Varela says. The survival for second-line regorafenib was estimated at 28 months versus 8 months with sorafenib, according to Varela.
There is some bias inthis real-life observational cohort
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More